President Trump signed an executive order on Monday calling for pharmaceutical companies to cut their drug prices for US consumers. Bernstein Senior Analyst, US Biopharmaceuticals Courtney Breen comments on whether the Trump administration ultimately has the power to force drug companies to do this. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Video Transcript 00:00 Speaker A Courtney, is it your understanding that President Trump, does he have the authority, Courtney, to do what he is proposing, what he wants to do here without congressional approval and legislation? 00:18 Courtney Great question. So, I think what was interesting in this executive order, where there is kind of a there is a request part of the order, and then there is a kind of threat part of the order. And in the request part is the suggestion that the government administration will pull together proposed MFN prices, propose these to companies, and then the companies get to choose to take actions to start lowering their US prices to come into line with those MFN prices. That perhaps is is kind of within the bounds of uh of some of the actions that could be taken if the industry decides to play ball. The second part, though, the threat if the industry doesn't play ball, is when legislation is required, kind of akin to what we saw with Biden and kind of the IRA, and the uh the MFP, the maximum fair price negotiations that are in place now for uh Medicare drugs. Um this is likely to require to be required to be instigated in legislation. Um and certainly through the press conference today, we saw reference to the fact that the intention is to load this legislation into the big beautiful bill that the Republicans are preparing on a number of topics and including tax cuts, um and ensure that that is a a a place for it to potentially pass. I think, however, there is a lot of of steps, a lot of detail, and the devil will really be in the in that detail as to whether this legislation can uh kind of proceed, doesn't have court issues going for going forward, and uh and we do actually see any implementation of this. I think is is still a question mark. 04:26 Speaker A So, Courtney, do you think that the drug companies will call the president's bluff and not lower the prices as he's requesting? 04:47 Courtney I think this is something that we're going to see playing out over the over the next few weeks to months. Uh they've given themselves uh the administration a 30-day deadline to to begin these conversations with pharma companies. Um bearing in mind, kind of the the the pharma lobbying body, Pharma, and uh many of the CEOs have been engaged with the administration kind of day in and day out over the past couple of months on this along with tariffs. So, kind of this will be a continuation of conversations that have probably already been happening in private. Um certainly what we did see in the executive order were a number of things that the drug companies have been wanting to achieve. They've been wanting to uh point the target to the countries outside the US and say, "Their drug prices are too low, uh and we need your help there." And they've also been pointing to the PBMs as being responsible for a large part of the reason as to why US drug prices are too high. So, there certainly were some olive branches given to the industry, um and definitely a reflection even of the industry lobbying lex lobbying language in this bill, sorry, in this executive order. Um and so when it comes to kind of is there going to be goodwill and trust from the industry, there might be a path here, but we'll just have to wait and see. Related Videos 02:19 Trump's Plan to Lower Drug Prices: Here's What We Know WSJ • 14 minutes ago 02:43 Both China and US Have Incentive To Make a Deal: Freund Bloomberg • 59 minutes ago 01:24 Watch: Last Living U.S. Hostage in Gaza Reunited with Family After Release WSJ • 2 hours ago 03:26 How Trump could go about executing order to slash drug prices Yahoo Finance Video • 3 hours ago View Comments
Trump's drug price order is part request, part threat: Analyst
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...